MHRA (Medicines and Healthcare products Regulatory Agency) takes soundings for five-year strategy
This article was originally published in Clinica
November 2 is the deadline for comments on the strategy document that has been published by the UK's Medicines and Healthcare products Regulatory Agency (MHRA), as it looks to its agenda and policies for the next five years.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.